Category: News

Risks for UK Biotech (The Times)

Novasecta’s Perspective on Brexit (Biotech and Money)

The year British biotechs will come of age (The Pharma Letter)

Pharma and academia are natural partners for R&D (MedNous)

Why the time has come for MidPharmas (MedNous)

Understanding and Choosing Your Partner (One Nucleus)

Pharma frenemies (The Economist)

Cost of pharma M&A doubles (Financial Times)

Agrochemicals and pharma are not compatible (Die Zeit)

Why Private Equity is Investing in Biopharma (MedNous)

Resources

Insights

Discover new perspectives and approaches to address industry challenges

Client Stories

Find out what our clients have achieved with us, and how

Media

Stay up to date with our press comment and specialist journal articles